FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149440145> ?p ?o ?g. }

• W2149440145 endingPage "1619" @default.
• W2149440145 startingPage "1611" @default.
• W2149440145 abstract "Atypical hemolytic uremic syndrome is characterized by vascular endothelial damage caused by complement dysregulation. Consistently, complement inhibition therapies are highly effective in most patients with atypical hemolytic uremic syndrome. Recently, it was shown that a significant percentage of patients with early-onset atypical hemolytic uremic syndrome carry mutations in diacylglycerol kinase-ε, an intracellular protein with no obvious role in complement. These data support an alternative, complement-independent mechanism leading to thrombotic microangiopathy that has implications for treatment of early-onset atypical hemolytic uremic syndrome. To get additional insights into this new form of atypical hemolytic uremic syndrome, the diacylglycerol kinase-ε gene in a cohort with atypical hemolytic uremic syndrome was analyzed.Eighty-three patients with early-onset atypical hemolytic uremic syndrome (<2 years) enrolled in the Spanish atypical hemolytic uremic syndrome registry between 1999 and 2013 were screened for mutations in diacylglycerol kinase-ε. These patients were also fully characterized for mutations in the genes encoding factor H, membrane cofactor protein, factor I, C3, factor B, and thrombomodulin CFHRs copy number variations and rearrangements, and antifactor H antibodies.Four patients carried mutations in diacylglycerol kinase-ε, one p.H536Qfs*16 homozygote and three compound heterozygotes (p.W322*/p.P498R, two patients; p.Q248H/p.G484Gfs*10, one patient). Three patients also carried heterozygous mutations in thrombomodulin or C3. Extensive plasma infusions controlled atypical hemolytic uremic syndrome recurrences and prevented renal failure in the two patients with diacylglycerol kinase-ε and thrombomodulin mutations. A positive response to plasma infusions and complement inhibition treatment was also observed in the patient with concurrent diacylglycerol kinase-ε and C3 mutations.Data suggest that complement dysregulation influences the onset and disease severity in carriers of diacylglycerol kinase-ε mutations and that treatments on the basis of plasma infusions and complement inhibition are potentially useful in patients with combined diacylglycerol kinase-ε and complement mutations. A comprehensive understanding of the genetic component predisposing to atypical hemolytic uremic syndrome is, therefore, critical to guide an effective treatment." @default.
• W2149440145 created "2016-06-24" @default.
• W2149440145 creator A5004118295 @default.
• W2149440145 creator A5016484576 @default.
• W2149440145 creator A5043796137 @default.
• W2149440145 creator A5046938997 @default.
• W2149440145 creator A5052276722 @default.
• W2149440145 creator A5053645267 @default.
• W2149440145 creator A5065412683 @default.
• W2149440145 creator A5069103831 @default.
• W2149440145 creator A5081352308 @default.
• W2149440145 creator A5091049255 @default.
• W2149440145 date "2014-09-01" @default.
• W2149440145 modified "2023-10-12" @default.
• W2149440145 title "Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome" @default.
• W2149440145 cites W1491837037 @default.
• W2149440145 cites W1545289546 @default.
• W2149440145 cites W1966590389 @default.
• W2149440145 cites W1971052994 @default.
• W2149440145 cites W1979236525 @default.
• W2149440145 cites W1980740976 @default.
• W2149440145 cites W2008607429 @default.
• W2149440145 cites W2017233426 @default.
• W2149440145 cites W2024751825 @default.
• W2149440145 cites W2043018978 @default.
• W2149440145 cites W2045534957 @default.
• W2149440145 cites W2059145105 @default.
• W2149440145 cites W2062890990 @default.
• W2149440145 cites W2076357933 @default.
• W2149440145 cites W2079104693 @default.
• W2149440145 cites W2087564804 @default.
• W2149440145 cites W2098315002 @default.
• W2149440145 cites W2098613222 @default.
• W2149440145 cites W2106578061 @default.
• W2149440145 cites W2118510193 @default.
• W2149440145 cites W2119057191 @default.
• W2149440145 cites W2123753762 @default.
• W2149440145 cites W2124841845 @default.
• W2149440145 cites W2127133726 @default.
• W2149440145 cites W2128624830 @default.
• W2149440145 cites W2129781700 @default.
• W2149440145 cites W2131509889 @default.
• W2149440145 cites W2132752562 @default.
• W2149440145 cites W2134898804 @default.
• W2149440145 cites W2135056130 @default.
• W2149440145 cites W2159986581 @default.
• W2149440145 cites W4210579787 @default.
• W2149440145 cites W4230935285 @default.
• W2149440145 doi "https://doi.org/10.2215/cjn.01640214" @default.
• W2149440145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4152807" @default.
• W2149440145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25135762" @default.
• W2149440145 hasPublicationYear "2014" @default.
• W2149440145 type Work @default.
• W2149440145 sameAs 2149440145 @default.
• W2149440145 citedByCount "59" @default.
• W2149440145 countsByYear W21494401452014 @default.
• W2149440145 countsByYear W21494401452015 @default.
• W2149440145 countsByYear W21494401452016 @default.
• W2149440145 countsByYear W21494401452017 @default.
• W2149440145 countsByYear W21494401452018 @default.
• W2149440145 countsByYear W21494401452019 @default.
• W2149440145 countsByYear W21494401452020 @default.
• W2149440145 countsByYear W21494401452021 @default.
• W2149440145 countsByYear W21494401452022 @default.
• W2149440145 countsByYear W21494401452023 @default.
• W2149440145 crossrefType "journal-article" @default.
• W2149440145 hasAuthorship W2149440145A5004118295 @default.
• W2149440145 hasAuthorship W2149440145A5016484576 @default.
• W2149440145 hasAuthorship W2149440145A5043796137 @default.
• W2149440145 hasAuthorship W2149440145A5046938997 @default.
• W2149440145 hasAuthorship W2149440145A5052276722 @default.
• W2149440145 hasAuthorship W2149440145A5053645267 @default.
• W2149440145 hasAuthorship W2149440145A5065412683 @default.
• W2149440145 hasAuthorship W2149440145A5069103831 @default.
• W2149440145 hasAuthorship W2149440145A5081352308 @default.
• W2149440145 hasAuthorship W2149440145A5091049255 @default.
• W2149440145 hasBestOaLocation W21494401451 @default.
• W2149440145 hasConcept C111684460 @default.
• W2149440145 hasConcept C126322002 @default.
• W2149440145 hasConcept C134018914 @default.
• W2149440145 hasConcept C14356644 @default.
• W2149440145 hasConcept C159654299 @default.
• W2149440145 hasConcept C179369057 @default.
• W2149440145 hasConcept C184235292 @default.
• W2149440145 hasConcept C189446657 @default.
• W2149440145 hasConcept C195794163 @default.
• W2149440145 hasConcept C203014093 @default.
• W2149440145 hasConcept C2777637130 @default.
• W2149440145 hasConcept C2777878052 @default.
• W2149440145 hasConcept C2777991916 @default.
• W2149440145 hasConcept C2779134260 @default.
• W2149440145 hasConcept C36020004 @default.
• W2149440145 hasConcept C54355233 @default.
• W2149440145 hasConcept C71924100 @default.
• W2149440145 hasConcept C86803240 @default.
• W2149440145 hasConceptScore W2149440145C111684460 @default.
• W2149440145 hasConceptScore W2149440145C126322002 @default.
• W2149440145 hasConceptScore W2149440145C134018914 @default.

• next